Medtox Scientific — Shareholder Meeting (May 2012)
23 slides from Medtox Scientific's shareholder meeting presentation, May 24, 2012
Slide 1: MEDTOX 2012 Annual Stockholders' Meeting
MEDTOX 2012 Annual Stockholders’ Meeting May 21, 2012
Slide 2: Financial Performance 2011 Year-End Objectives
Financial Performance 2011 Year-End > Objectives 1. Maximize Operating Income 2. Increase Operating Cash Flow 3. Strengthen our Balance Sheet
Slide 3: Maximize Operating Income
Maximize Operating Income O Revenue Growth O Improved Gross Profit O Reduced SG&A expenses as a % of Sales
Slide 4: Revenue Growth
Revenue Growth (in thousands) 2011 2010 Revenues $108,149 $97,101 > Annual Growth 11.4% > Five year CAGR 9.2%
Slide 5: Drugs-of-Abuse Testing Services
Drugs-of-Abuse Testing Services Annual Revenue (millions) 413 38,7 40.0 39.6 36.0 2003 2004 2005 2006 2007 2008 2009 2010 2011 > 2011 Revenue Growth 4.3%
Slide 6: Clinical and Other Lab Services
Clinical and Other Lab Services Annual Revenue (millions) 40.0 35.0 an satel 29.9 25.0 19.3 20.0 16.7 382 ts0 15:9 14.6 14.9 10.0 5.0 0.0 2003 2004 2005 2006 2007 2008 2009 2010 2011 > 2011 Revenue Growth 16.5%
Slide 7: Clinical Trial Services
Clinical Trial Services Annual Revenue (millions) iz 10 9.7 2. z 68 6.9 6 43 45 zs Ba 24 | 20 43 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 > 2011 Revenue Growth 28.9%
Slide 8: Product Sales
Product Sales Annual Revenue (millions) 25.0 19,.019-7 22.3 20.1 20.0 ' 15.8 15.0 13,5—14:5 12.0 10.0 — 5.0 2003 2004 2005 2006 2007 2008 2009 2010 2011 > 2011 Revenue Growth 11.1%
Slide 9: Improved Gross Profit
Improved Gross Profit (inthousands) 2011 2010 Gross Profit $44,835 $39,640 Gross Margin 41.5% 40.8% > Gross profit increased 13.1% to $44.8 million > Gross margin increased 70 basis points to 41.5% of revenue
Slide 10: Reduced Selling, General & Administrative
Reduced Selling, General & Administrative Expenses as a Percentage of Sales % of % of (in thousands) 2011 Sales 2010 Sales SG&A Expense $35,144 32.5% $32,691 33.7% > SG&A Expense as a % of sales decreased 120 basis points
Slide 11: Maximize Operating Income
Maximize Operating Income (in thousands) 2011 2010 Operating Income $7,172 $4,688 > Operating income increased 53.0%
Slide 12: Earnings Per Share
Earnings Per Share 2011 2010 Diluted Earnings Per Common Share $0.49 $0.34 > Diluted earnings per share increased 44.1%
Slide 13: Increase Cash Flows
Increase Cash Flows 2010 Net Cash Provided by Operating Activities (in thousands) $10,106
Slide 14: Balance Sheet
Balance Sheet (in thousands) Dec Dec 2011 2010 Assets Cash and cash equivalents $5,269) $1,285 Accounts recelvable, net 17,209| 19,575 Inventories 4,568 3,902 Other current assets 4,480 5,297 Building, equipment and improvements, net 28,105| 28,164 Other assets 17,223 | 17,234 Total Assets $76,854 |
Slide 15: Financial Performance First Quarter 2012
Financial Performance First Quarter 2012
Slide 16: Revenue - Q1
Revenue - Q1 Mar 31, Mar 31, (inthousands) 2012-QTD _2011-QTD Revenues $28,580 $25,097 > Ql Revenue increased 13.9%
Slide 17: Gross Profit - Q1
Gross Profit - Q1 Mar 31, Mar 31, (in thousands) 2012-QTD 2011-QTD Gross Profit $11,856 $9,812 Gross Margin 41.5% 39.1% > Gross profit increased 20.8% to $11.9 million > Gross margin increased 240 basis points to 41.5% of revenue
Slide 18: Selling, General & Administrative Expenses - Q1
ing, General & Administrative Expenses - Q1 Mar31, of Mar 31, of (in thousands) 2012-QTD sales __-2011-QTD__ sales SG&A Expense $8,807 30.8% $7,985 31.8% > SG&A Expense as a % of sales decreased 100 basis points
Slide 19: Operating Income - Q1
Operating Income - Q1 Mar 31, Mar 31, (inthousands) 2012-QTD _2011-QTD Operating Income $2,360 $1,233 > Operating income increased 91.4%
Slide 20: Earnings Per Share
Earnings Per Share Mar 31, 2012 Mar 31, 2011 QTD i) Diluted Earnings Per Common Share $0.17 $0.09 > Diluted earnings per share increased 88.9%
Slide 21: Net Cash Provided by Operating Activities
Net Cash Pro: (in thousands) led by Operating Acti es Mar 31, Mar 31, 2012-QTD | 2011-aTD Net cash provided by operating activities $2,738 | $1,302
Slide 22: Balance Sheet
Balance Sheet (in thousands) March | December 2012 2011 Assets Cash and cash equivalents $7,048) $5,269 Accounts receivable, net 18,855 17,209 Inventories 4,728 4,568 Other current assets 4,040 4,480 Bullding, equipment and Improvements, net 27,166 28,105 Otherassets 17,160 17,223 Total Assets $78,9
Slide 23: MEDTOX 2012 Annual Stockholders' Meeting
MEDTOX 2012 Annual Stockholders’ Meeting May 21, 2012